Diabetes mellitus (DM) and congestive heart failure (HF) commonly coexist in the same patient, and the presence of DM in HF patients is associated with increased adverse events compared with patients without DM. Recent guidelines regarding glycemic control stress individualization of glycemic therapy based on patient comorbid conditions and potential adverse effects of medical therapy. This balance in glycemic control may be particularly relevant in patients with DM and HF. In this review, we address data regarding the influence that certain HF medications may have on glycemic control. Despite potential modest changes in glycemic control, clinical benefits of proven pharmacologic HF therapies extend to patients with DM and HF. In addition, we review potential benefits and challenges associated with commonly used glycemic medications in HF patients. Finally, recent data and controversies on optimal glycemic targets in HF patients are discussed. Given the large number of patients with DM and HF and the health burden of these conditions, much needed future work is necessary to define the optimal glycemic treatment in HF patients with DM.
|Journal||American Journal of Cardiology|
|Issue number||SUPPL. 9|
|State||Published - Nov 6 2012|
Bibliographical noteFunding Information:
David Aguilar, MD, has received consulting fees from Amylin and Sanofi-Aventis, is a research investigator in the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial and the Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL) trial and is supported by an NHLBI Mentored Career Development award (5K01-HL092585-03).
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine